Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017

Marco Heppe Montero, Ruth Gil-Prieto, Stefan Walter, Fernando Aleixandre Blanquer, Ángel Gil De Miguel, Marco Heppe Montero, Ruth Gil-Prieto, Stefan Walter, Fernando Aleixandre Blanquer, Ángel Gil De Miguel

Abstract

Bronchiolitis represents a heavy burden of disease in children under 2 years of age in our society due to the high infectivity of the Respiratory Syncytial Virus [RSV] and the vulnerability of the youngest children.The objective of this retrospective epidemiological study was to show the burden of severe bronchiolitis in Spain through population-based estimates of hospitalizations due to bronchiolitis in children up to 24 months old during a 6-year period (2012-2017).A total of 100,115 cases of bronchiolitis required hospitalization in Spain from 2012 to 2017. Most cases of bronchiolitis that required hospitalization were in infants under 3 months of age. The hospitalization rate for bronchiolitis for children under 1 year of age was 3,838.27 per 100,000 healthy children. During the 6-year study period, a total of 82 deaths due to bronchiolitis were reported among hospitalized infants. Among these deaths, more than 50% were in patients younger than 3 months of age. The annual average cost to the National Health Care System was €58 M, with a mean hospitalization cost of €3,512 per case.

Keywords: Bronchiolitis; Spain; children; epidemiology; immunotherapy; respiratory syncytial virus; vaccine.

Figures

Figure 1.
Figure 1.
Incidence of hospitalization associated with bronchiolitis per 100,000 children by age in month in Spain.
Figure 2.
Figure 2.
Incidence of hospitalization associated with bronchiolitis per 100,000 children by calendar month in Spain.

References

    1. Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, Gallardo-Pino C, Gil-de-Miguel A.. Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain. Medicine (Baltimore) [Internet]. 2015;94(21):e831. Available from .
    1. Sardón O, Korta J, Pérez-Yarza G. E. Bronquiolitis. An Pediatría Contin [Internet]. Elsevier; 2007. Dec 1;5(6):332–7. [accessed 2018 Jul 14]. .
    1. Thwaites RS, Coates M, Ito K, Ghazaly M, Feather C, Abdulla F, Tunstall T, Jain P, Cass L, Rapeport G, et al. Reduced nasal viral load and IFN responses in infants with respiratory syncytial virus bronchiolitis and respiratory failure. Am J Respir Crit Care Med [Internet]. 2018;198(8):1074–84.
    1. Higgins D, Trujillo C, Keech C. Advances in RSV vaccine research and development - A global agenda. Vaccine [Internet]. 2016;34(26):2870–75. Elsevier Ltd. doi:10.1016/j.vaccine.2016.03.109.
    1. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. doi:10.1016/S0140-6736(17)30938-8.
    1. Karron RA, Black RE. Determining the burden of respiratory syncytial virus disease: the known and the unknown. Lancet [Internet]. 2017;390(10098):917–18. doi:10.1016/S0140-6736(17)31476-9.
    1. Blecua C, Praena M, Águeda C, Isabel GM, Mora Gandarillas M, Luis Montón Alvarez J, Antonio Castillo Laita J. Diagnóstico Tratamiento en Atención Primaria. Bronquiolitis [Internet]. 2015. .
    1. Luz García MA, Murua JK. ACC. Bronquiolitis aguda viral. ©asociación Española de Pediatría. Internet]. 2017;1(1):85–102. .
    1. Muñoz-Quiles C, López-Lacort M, Úbeda-Sansano I, Alemán-Sánchez S, Pérez-Vilar S, Puig-Barberà J, Díez-Domingo J. Population-based analysis of bronchiolitis epidemiology in Valencia, Spain. Pediatr Infect Dis J. 2016;35(3):275–80. doi:10.1097/INF.0000000000000993.
    1. Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, Simões EAF, Carbonell-Estrany X. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western Countries. Infect Dis Ther. 2016;5(3):271–98. doi:10.1007/s40121-016-0123-0.
    1. Meer HC. Viral Bronchiolitis in Children. N Engl J Med. Internet]. 2016;374(1):62–72. .
    1. Weinberg GA. Respiratory syncytial virus mortality among young children. Lancet Glob Heal [Internet]. 2017;5(10):e951–2. doi:10.1016/S2214-109X(17)30348-0.
    1. Ministerio de Sanidad y Consumo . Clasificación internacional de enfermedades 9ª revisión, modificación clínica. 1994.
    1. Instituto Nacional de la Salud. Subdirección General de Coordinación administrativa . Conjunto Mínimo Básico de Datos. Hospitales de INSALUD 2001. Madrid; 2002. .
    1. Rivero Cuadrado A. El conjunto mínimo básico de datos en el SNS: inicios y desarrollo actual. Rev Fuentes Estadísticas. 2000;49:18–19. .
    1. Sánchez Martín M, Calvo Rey C. Bronquiolitis Aguda. In: Guerrero-Fdez J, Cartón SA, Barreda BA, Menéndez SJ, Ruiz DJ, editors. Manual de diagnóstico y terapéutica en pediatría. 6ª Edición. Madrid: Editorial Panamericana; 2017. p. 1379–85.
    1. Schreyögg J, Stargardt T, Tiemann O, Busse R. Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries. Health Care Manag Sci. 2006;9(3):215–23. doi:10.1007/s10729-006-9040-1.
    1. Cattoir L, Vankeerberghen A, Boel A, Van Vaerenbergh K, De Beenhouwer H. Epidemiology of RSV and hMPV in Belgium: a 10-year follow-up. Acta Clin Belgica Int J Clin Lab Med [Internet]. 2019;74(4):229–35. doi:10.1080/17843286.2018.1492509.
    1. James E, Crowe J. Virus Respiratorio Sincitial. En: tratado de Pediatría. Nelson, Kliegman, Stanton, St. Geme, Schor. 20ª Edición. Barcelona: Editorial Elsevier; 2016. Vol. 1. p. 1683–86.
    1. ECDC Expert Consultation Meeting, Stockholm, 23-24 November 2015. Workshop on burden of RSV disease in Europe.
    1. Buchwald AG, Tamboura B, Tennant SM, Haidara FC, Coulibaly F, Doumbia M. Epidemiology, risk factors, and outcomes of respiratory syncytial virus infections in newborns in Bamako, Mali. Clin Infect Dis. 2019;(April). doi:10.1093/cid/ciy427.
    1. Carbonell-Estrany X, Figueras-Aloy J, Law BJ, Infección Respiratoria Infantil por Virus Respiratorio Sincitial Study Group, Pediatric Investigators Collaborative Network on Infections in Canada Study Group . Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J. 2004. Nov;23(11 Suppl):S193–201. doi:10.1097/01.inf.0000144664.31888.53
    1. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, Munich RSV Study Group . Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003. Apr;162(4):230–36. Epub 2003 Mar 1. doi:10.1007/s00431-002-1105-7
    1. Gouyon JB, Rozé JC, Guillermet-Fromentin C, Glorieux I, Adamon L, DI Maio M, Miloradovich T, Anghelescu D, Pinquier D, Escande B, Elleau C. Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study. Epidemiol Infect. 2013. Apr;141(4):816–26. doi:10.1017/S0950268812001069.
    1. Falagas ME, Mourtzoukou EG, Vardakas KZ. Sex differences in the incidence and severity of respiratory tract infections. Respir Med. 2007. Sep;101(9):1845–63. doi:10.1016/j.rmed.2007.04.011. Epub 2007 Jun 1.
    1. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143:S118–26. doi:10.1067/S0022-3476(03)00511-0.
    1. Chu HY, Tielsch J, Katz J, Magaret AS, Khatry S, LeClerq SC, Shrestha L, Kuypers J, Steinhoff MC, Englund JA. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal. J Clin Virol. 2017;95:90–95. October 2016. doi:10.1016/j.jcv.2017.08.017.
    1. Gopal DP, Barber J, Toeg D. Pertussis (whooping cough). BMJ [Internet]. 2019. February;364:4–11. doi:10.1136/bmj.l401.
    1. Murthy S, Godinho MA, Lakiang T, Lewis MGG, Lewis L, Nair NS. Efficacy and safety of pertussis vaccination in pregnancy to prevent whooping cough in early infancy. Cochrane Database Syst Rev. 2018;2018:4.
    1. Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization Meeting held on 23-24 March 2015. Vaccine. 2016;34(2):190–97. doi:10.1016/j.vaccine.2015.05.093.
    1. Scheltema NM, Kavelaars XM, Thorburn K, Hennus MP, van Woensel JB, van der Ent CK, Borghans JAM, Bont LJ, Drylewicz J. Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy. Vaccine [Internet]. 2018;36(31):4693–700. doi:10.1016/j.vaccine.2018.06.021.
    1. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meer HC, Fulton DR, Welliver RC. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329(21):1524–30. doi:10.1056/NEJM199311183292102.
    1. The IMpact-RSV Study Group . Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531–37. doi:10.1542/peds.102.3.531.
    1. Feltes TF, Cabalka AK, Meer HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM, The Cardiac Synagis Study Group F. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532–40. doi:10.1067/S0022-3476(03)00454-2.
    1. Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70(2):18691. doi:10.1203/PDR.0b013e318220a553.
    1. Carbonell-Estrany X, Simões EA, Dagan R. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125(1):e35–e51. doi:10.1542/peds.2008-1036.
    1. O’Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised doubleblind placebo-controlled trial. Lancet Infect Dis. 2015;15:1398–408. doi:10.1016/S1473-3099(15)00247-9.
    1. Pamela Griffin M, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, et al., Nirsevimab Study Group . Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020. Jul 30;383(5):415–25. doi:10.1056/NEJMoa1913556.
    1. Synagis (palivizumab): highlights of prescribing information. Gaithersburg (MD): MedImmune; 2017.
    1. Capizzi A, Silvestri M, Orsi A, Cutrera R, Rossi GA, Sacco O. The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence. Ital J Pediatr. 2017;43(1):71. doi:10.1186/s13052-017-0390-8.
    1. Acero-Bedoya S, Wozniak PS, Sánchez PJ, Ramilo O, Mejias A. Recent Trends in RSV Immunoprophylaxis: clinical Implications for the Infant. Am J Perinatol [Internet]. 2019;36(S02):S63–7.
    1. Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, Manzoni P, Mejias A, Nair H, Papadopoulos NG, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3(11):888–900. doi:10.1016/S2213-2600(15)00255-6.
    1. Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18(10):e295–311. doi:10.1016/S1473-3099(18)30292-5.
    1. Mejias A, Garcia-Maurino C, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine [Internet]. 2017;35(3):496–502. doi:10.1016/j.vaccine.2016.09.026.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner